SCYNEXIS, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visit www.scynexis.com.
Ticker:
SCYX
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2000
Main Therapeutic Focus:
Lead Product in Development:
Ibrexafungerp
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & Chief Executive Officer
Scynexis, Inc.